Peter Venner

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf et al. · New England Journal of Medicine · 2014 · 3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan et al. · Journal of Clinical Oncology · 2009 · 2.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

I. F. Tannock, David Osoba, Martin R. Stockler et al. · Journal of Clinical Oncology · 1996 · 1.6K citations

Medicine, Oncology, Pharmacotherapy +17

Resistance Exercise in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

Roanne Segal, Robert D. Reid, Kerry S. Courneya et al. · Journal of Clinical Oncology · 2003 · 783 citations

Medicine, Endocrinology, Oncology +17

Intermittent versus Continuous Androgen Deprivation in Prostate Cancer

Maha Hussain, Catherine M. Tangen, Donna L. Berry et al. · New England Journal of Medicine · 2013 · 568 citations · Full text

Medicine, Oncology, Urology +14